FDA approves a novel drug for schizophrenia

Mechanism and Trial Data

• Drug is a xanomeline/trospium combo: central muscarinic (M1/M4) agonist plus a peripherally acting antagonist to blunt GI and other peripheral side effects.
• Some find the “agonist + antagonist for same pharmacophore” design elegant; others question whether central analgesic/psychoactive and peripheral effects can really be separated (compared to opioids discussion).
• Linked trials include short 5‑week efficacy studies and longer 52‑week open‑label safety studies; some commenters want more long‑term outcome data beyond PANSS scores.

Clinical Promise vs. Risks

• Many see it as a major advance over dopaminergic antipsychotics, which are described as “chemical lobotomy” with weight gain, metabolic issues, movement disorders, and emotional blunting causing non‑adherence.
• Others stress that “feeling like a different person” is itself a serious harm, not just a trade‑off.
• There is skepticism that any antipsychotic is benign; concerns about withdrawal, long‑term brain changes, and whether the new drug will mainly sedate rather than treat.

Price, R&D, and Pharma Economics

• List price $22.5k/year ($1,850/month wholesale) draws criticism, especially vs. expected low manufacturing cost and much lower prices anticipated in Europe/generics.
• Defenders argue high prices are needed to recoup a $14B acquisition and many failed R&D bets; opponents note the molecule was originally developed cheaply in the UK and that public/taxpayer funding underpins much basic research.
• Debate over whether 20% profit on successful drugs is sufficient, and whether US overpayment subsidizes global pharma.

Regulation and the FDA

• Some portray the FDA as captured and over‑lenient with psychiatric drugs; others say it is pushed both to approve “snake oil” and then blamed when it does.
• Disagreement over whether FDA’s gatekeeping is primarily protecting patients or protecting industry.

Nature of Schizophrenia and Psychiatry

• Strong clash between:
  • View that schizophrenia is a well‑defined, devastating brain illness where antipsychotics are often life‑saving.
  • View that diagnoses are subjective, DSM is “bible‑like,” and antipsychotics themselves can induce psychosis‑like symptoms, long‑term damage, and reduced lifespan.
• Some criticize simplistic neurotransmitter stories (e.g., serotonin for depression) and extend that skepticism to this mechanism.
• Others counter that many chronic diseases require lifelong meds; lack of a “cure” doesn’t invalidate treatment.

Trauma, Psychotherapy, and Alternatives

• Multiple citations link childhood trauma and interpersonal abuse to higher risk and severity of psychosis, proposing trauma‑focused therapies (e.g., CBT, EMDR) as important, sometimes with reported remission cases.
• Critics argue schizophrenia is primarily biological, that psychotherapy alone is rarely sufficient, and that telling patients it’s “just trauma” can be harmful.

Homelessness and Social Policy

• Repeated discussion of homelessness:
  • One camp sees effective antipsychotics as potentially transformative for a substantial subset of chronically homeless people with psychosis.
  • Another stresses that housing, income, and basic healthcare (“housing first”) are prerequisites; drugs alone won’t reach most homeless people or address financial drivers.

Healthcare Systems and Access

• Extensive back‑and‑forth on US vs. public systems:
  • Some defend high US prices as fueling global innovation.
  • Others note worse US health outcomes and argue for nationalized or heavily regulated healthcare and price controls.
• Concern that homeless and poor patients will be last to benefit, waiting for generics.

DIY, Generics, and Grey‑Market Access

• A few mention buying raw chemicals by CAS number or compounding to bypass pricing, which others call dangerous and irresponsible.
• Some hope for generics in Europe at very low cost; others mention “pharma hacking” collectives, raising safety and regulatory questions.

Vitamins and Non‑Mainstream Claims

• One commenter asserts schizophrenia can be cured with niacin; others rebut that megavitamin therapy hasn’t held up under replication, while acknowledging micronutrient deficiencies (e.g., B6, C) can influence mood and cognition.

Lived Experience and Medication Adherence

• Several share personal or family stories:
  • Catastrophic outcomes when people stop meds due to side effects or lack of insight (anosognosia).
  • Others report severe harms from meds and better functioning after tapering off, fueling distrust of psychiatry.
• Tension between calls for long‑acting injectables and more coercive treatment vs. strong emphasis on autonomy and personalized, non‑pharma‑dominated care.